ovarian cancer | pharmaphorum

Skip to main content

Wednesday 1 April 2026

BlueSky linkedin youtube

header links

Get Newsletters
Media Kit

Pharmaphorum menu first category

News
Views & Analysis
Deep Dive
Webinars
Podcasts
Videos
Spotlight on
Events

close

SECTION

News
Views & Analysis
Deep Dive
Webinars
Podcasts
Videos
White Papers
Events

Channels

Channels

Sales & Marketing
R&D
Digital
Market Access
Oncology
Patients
Spotlight On

Channels

Sales & Marketing
R&D
Digital
Market Access
Oncology
Patients
Spotlight On

SUB NAVIGATION

Live Coverage
Partner Content
About us
Work for us
Contribute
Contact us
Advertise

Newsletters and Deep Dive digital magazine

youtube linkedin BlueSky

ovarian cancer

News

clovis-oncology

Rubraca outshines rivals in ovarian cancer maintenance thera...

Clovis' Rubraca, the drug showing significant benefits for all ovarian cancer patients in a maintenance setting – and better results than its rivals.

News

astrazeneca-sign

AZ and Merck & Co ovarian cancer drug gets expanded US use

FDA approves Lynparza's use in a wider group of women.

News

parsortix2

Angle poised to take on US cancer diagnostics market

Circulating tumour cell test could help select drug therapy.

News

clovis-oncology

Clovis looks for new drugs after Rubraca success

US biotech looks to bolster pipeline.

News

AstraZeneca (AZ)

AZ highlights data from next-gen oncology drugs at ASCO

Tesara and Takeda among other companies to publish data.

News

AbbVie-HQ

Doubts over AbbVie PARP inhibitor after double trial failure

Veliparib fails in two phase 3 trials.

Load more results

Editor's Picks

Novartis snaps up PI3Kα breast cancer drug in $3bn deal

US court says pharma giants must face False Claims suit

Meningitis outbreak in UK prompts call to widen vaccination

US judge rules Kennedy's vaccine changes 'unlawful'

Generic semaglutide in India, and other weight-loss news

News

Lilly bags FDA okay for Wegovy pill rival orforglipron

Lilly bags FDA okay for Wegovy pill rival orforglipron

Eli Lilly has claimed US approval for oral GLP-1 agonist orforglipron, setting up a market clash with Novo Nordisk's first-to-market Wegovy pill.

/themes/custom/pharmaphorum_theme/library/img/article-label-image/ondemand.png

Sales & Marketing

Using AI-driven synthetic personas to take your insights further

Sponsored

Using AI-driven synthetic personas to take your insights fur...

As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.

Pharmaphorum Menu

Digital
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Market Access
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Oncology
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Patients
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
R&D
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Sales & Marketing
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Spotlight on

Sign up for email newsletters and Deep Dive

Get Newsletters

youtube linkedin BlueSky

About us Advertising Contact us

Contribute Cookie Policy Privacy Policy

Terms & Conditions Work for us

The rights of trademark owners are acknowledged. Website and content copyright © 2009-2026, pharmaphorum media limited or its licensors; all rights reserved. pharmaphorum – an EVERSANA company

The rights of trademark owners are acknowledged. Website and content copyright © 2009-2026, pharmaphorum media limited or its licensors; all rights reserved. pharmaphorum – an EVERSANA company